Cristiana Tanase
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Cristiana Tanase has a total of 346 co-authors. Here are the top co-authors by number of shared publications:
- Radu Albulescu
Faculty of Medicine, Titu Maiorescu University, 031593 Bucharest, Romania
38 shared publications - Monica Neagu
”Victor Babes” National Institute, 99-101 Splaiul Independentei, 050096 Bucharest, Romania
25 shared publications - Ana-Maria Enciu
Carol Davila University of Medicine and Pharmacy, 050047 Bucharest, Romania
23 shared publications - Elena Codrici
Victor Babes National Institute of Pathology, 050096 Bucharest, Romania
18 shared publications - Carolina Constantin
Faculty of Medicine, The “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania
16 shared publications Elena Codrici
“Victor Babes” National Institute of Pathology, Biochemistry-Proteomics Department, Bucharest, Romania
13 shared publications
Latest Publications
- Open Access
- 22 June 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (6) , 51339
Comparative Analysis of Ultra-Low Versus Hydrogel Growing Conditions for Patient-Derived Glioma Organoids
Background:Most data related to high-grade glioma and glioblastoma (GBM) 3D models refer to ultra-low/suspension cultivation systems, for several reasons: easy to initiate, high penetrability of treatments, ease of harvesting for downstream analysis. However, the major limitation of these models is the absence of the extracellular matrix, which enables the specific, local invasiveness of these aggressive brain tumors.Aim:This study provides a comparison between ultra-low and several extracellular matrix (ECM) and hydrogel culture conditions for various grades of patient-derived glioma organoids, in terms of cell growth, invasiveness, and release of cytokines/chemokines, as a model for downstream analysis of soluble factors.Materials and Methods:Patient-derived glioma organoids were initiated in three different conditions: ultra-low attachment(UL), 3D Matrigel, and dextran-based hydrogels. Human endothelial cells were used for tube assay co-cultures and human normal monocyte cell line SC to assess monocyte invasion and interaction with tumor organoids.Results:UL conditions supported organoid formation with better growth rate and easy passaging, and reliable detection of secreted cytokines and chemokines, closely mirroring qualitative secretory profiles observed in tumor explants. In contrast, ECM-based systems enabled invasive growth patterns and co-culture assays, but with a restricted immune cell infiltration and with a reduced detectable level of soluble factors. While qualitative cytokine signatures were preserved across culture platforms, substantial quantitative differences were observed, highlighting the influence of matrix composition on measurable outputs. Preliminary data showed that organoid-forming capacity indicated no clear association with Isocitrate Dehydrogenase 1 (IDH1) mutational status in the tested samples.Conclusion:Our findings indicate that UL and ECM-based models provide complementary information and recommend a dual-platform cell culture initiation strategy to maximize robustness and translational relevance in patient-derived glioma research.
- 22 June 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (6) , 51339
Open AccessComparative Analysis of Ultra-Low Versus Hydrogel Growing Conditions for Patient-Derived Glioma Organoids
Background:Most data related to high-grade glioma and glioblastoma (GBM) 3D models refer to ultra-low/suspension cultivation systems, for several reasons: easy to initiate, high penetrability of treatments, ease of harvesting for downstream analysis. However, the major limitation of these models is the absence of the extracellular matrix, which enables the specific, local invasiveness of these aggressive brain tumors.Aim:This study provides a comparison between ultra-low and several extracellular matrix (ECM) and hydrogel culture conditions for various grades of patient-derived glioma organoids, in terms of cell growth, invasiveness, and release of cytokines/chemokines, as a model for downstream analysis of soluble factors.Materials and Methods:Patient-derived glioma organoids were initiated in three different conditions: ultra-low attachment(UL), 3D Matrigel, and dextran-based hydrogels. Human endothelial cells were used for tube assay co-cultures and human normal monocyte cell line SC to assess monocyte invasion and interaction with tumor organoids.Results:UL conditions supported organoid formation with better growth rate and easy passaging, and reliable detection of secreted cytokines and chemokines, closely mirroring qualitative secretory profiles observed in tumor explants. In contrast, ECM-based systems enabled invasive growth patterns and co-culture assays, but with a restricted immune cell infiltration and with a reduced detectable level of soluble factors. While qualitative cytokine signatures were preserved across culture platforms, substantial quantitative differences were observed, highlighting the influence of matrix composition on measurable outputs. Preliminary data showed that organoid-forming capacity indicated no clear association with Isocitrate Dehydrogenase 1 (IDH1) mutational status in the tested samples.Conclusion:Our findings indicate that UL and ECM-based models provide complementary information and recommend a dual-platform cell culture initiation strategy to maximize robustness and translational relevance in patient-derived glioma research.
- Open Access
- 29 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (3) , 1338
Sleep Deficit and Inflammatory Markers as Combined Risk Factors for Glaucoma Progression: A Prospective Longitudinal Observational Cohort Study
Glaucoma progression differs markedly between individuals despite comparable intraocular pressure control, implying additional modifiable contributors to neurodegeneration. We evaluated the joint impact of sleep deficit and inflammatory cytokine trajectories on retinal nerve fiber layer (RNFL) loss. In this 24-month prospective longitudinal observational cohort, 57 participants (19 controls, 19 prostaglandin-treated glaucoma, 19 untreated glaucoma) underwent spectral-domain OCT, validated sleep assessment, and serial IL-6 and TNF-α profiling. Longitudinal models tested independent and interactive effects of sleep deficit and inflammation on RNFL change, and mediation analyses assessed whether inflammation explains the sleep–progression association. RNFL loss rates were −0.20 ± 0.10 μm/year (controls), −1.06 ± 0.89 μm/year (treated), and −1.94 ± 0.78 μm/year (untreated; p < 0.001). Sleep deficit correlated with RNFL loss in glaucoma (r = −0.41, p = 0.010) but not controls, with stronger effects in untreated disease (p = 0.034). Each hour of sleep deficit was associated with 0.09–0.11 μm/year faster RNFL loss (p < 0.05). A combined sleep–inflammation model improved risk stratification (C-statistic = 0.68). Mediation was not supported. Sleep deficit and inflammatory cytokines act as parallel, independent risk factors for glaucoma progression. Integrating sleep and inflammatory profiling may enhance personalized risk assessment beyond pressure-based management.
- 29 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (3) , 1338
Open AccessSleep Deficit and Inflammatory Markers as Combined Risk Factors for Glaucoma Progression: A Prospective Longitudinal Observational Cohort Study
Glaucoma progression differs markedly between individuals despite comparable intraocular pressure control, implying additional modifiable contributors to neurodegeneration. We evaluated the joint impact of sleep deficit and inflammatory cytokine trajectories on retinal nerve fiber layer (RNFL) loss. In this 24-month prospective longitudinal observational cohort, 57 participants (19 controls, 19 prostaglandin-treated glaucoma, 19 untreated glaucoma) underwent spectral-domain OCT, validated sleep assessment, and serial IL-6 and TNF-α profiling. Longitudinal models tested independent and interactive effects of sleep deficit and inflammation on RNFL change, and mediation analyses assessed whether inflammation explains the sleep–progression association. RNFL loss rates were −0.20 ± 0.10 μm/year (controls), −1.06 ± 0.89 μm/year (treated), and −1.94 ± 0.78 μm/year (untreated; p < 0.001). Sleep deficit correlated with RNFL loss in glaucoma (r = −0.41, p = 0.010) but not controls, with stronger effects in untreated disease (p = 0.034). Each hour of sleep deficit was associated with 0.09–0.11 μm/year faster RNFL loss (p < 0.05). A combined sleep–inflammation model improved risk stratification (C-statistic = 0.68). Mediation was not supported. Sleep deficit and inflammatory cytokines act as parallel, independent risk factors for glaucoma progression. Integrating sleep and inflammatory profiling may enhance personalized risk assessment beyond pressure-based management.
- Open Access
- 26 November 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (12) , 2884
Unlocking the Sugar Code: Implications and Consequences of Glycosylation in Alzheimer’s Disease and Other Tauopathies
Alzheimer’s disease (AD) is the most prevalent cause of dementia, characterized by progressive cognitive decline, amyloid-β (Aβ) plaques, and neurofibrillary tangles composed of hyperphosphorylated tau protein. Other tauopathies, including frontotemporal lobar degeneration (FTLD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD) share pathological hallmarks centered on abnormal tau biology. Increasing evidence highlights the role of post-translational modifications in modulating these pathogenic processes. Among these, glycosylation, the enzymatic attachment of glycans to proteins or lipids, has emerged as a critical regulator of protein folding, trafficking, aggregation, and clearance. Both N-linked glycosylation (N-glycosylation) and O-linked glycosylation (O-glycosylation) influence tau stability, Aβ processing, receptor signaling, synaptic integrity, and neuroinflammation. Dysregulated glycosylation patterns have been documented in brains and cerebrospinal fluid (CSF) of AD patients, suggesting biomarker potential and novel therapeutic targets. Moreover, glycosyltransferases and glycosidases show altered expression in neurodegeneration, linking metabolic and inflammatory pathways to tauopathy progression. This review synthesizes current evidence on the implications and consequences of glycosylation in AD and other tauopathies, integrating mechanistic, pathological, and clinical findings. We also discuss advances in glycoproteomics, the interplay between glycosylation and phosphorylation, and the translational potential of targeting glycosylation pathways for diagnosis and therapy.
- 26 November 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (12) , 2884
Open AccessUnlocking the Sugar Code: Implications and Consequences of Glycosylation in Alzheimer’s Disease and Other Tauopathies
Alzheimer’s disease (AD) is the most prevalent cause of dementia, characterized by progressive cognitive decline, amyloid-β (Aβ) plaques, and neurofibrillary tangles composed of hyperphosphorylated tau protein. Other tauopathies, including frontotemporal lobar degeneration (FTLD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD) share pathological hallmarks centered on abnormal tau biology. Increasing evidence highlights the role of post-translational modifications in modulating these pathogenic processes. Among these, glycosylation, the enzymatic attachment of glycans to proteins or lipids, has emerged as a critical regulator of protein folding, trafficking, aggregation, and clearance. Both N-linked glycosylation (N-glycosylation) and O-linked glycosylation (O-glycosylation) influence tau stability, Aβ processing, receptor signaling, synaptic integrity, and neuroinflammation. Dysregulated glycosylation patterns have been documented in brains and cerebrospinal fluid (CSF) of AD patients, suggesting biomarker potential and novel therapeutic targets. Moreover, glycosyltransferases and glycosidases show altered expression in neurodegeneration, linking metabolic and inflammatory pathways to tauopathy progression. This review synthesizes current evidence on the implications and consequences of glycosylation in AD and other tauopathies, integrating mechanistic, pathological, and clinical findings. We also discuss advances in glycoproteomics, the interplay between glycosylation and phosphorylation, and the translational potential of targeting glycosylation pathways for diagnosis and therapy.
- Open Access
- 6 November 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (21) , e70889
Therapeutic Strategies Targeting Anti‐ CD47 Therapies in Glioblastoma Multiforme: Lead or Dead End?
Glioblastoma multiforme (GBM) remains the most aggressive primary brain tumour in adults, characterised by marked cellular heterogeneity, stem‐like subpopulations, and profound resistance to standard therapies. The failure of conventional approaches underscores the need for novel immunotherapeutic strategies that can effectively overcome tumour immune evasion. Multiple therapeutic strategies have been explored to disrupt CD47 signalling in GBM, including monoclonal antibodies, soluble SIRPα fusion proteins, recombinant or peptide fragments derived from TSP‐1, dual CD47/CD36 inhibitors, and antisense oligonucleotides. Overall, anti‐CD47 therapy represents a promising but incomplete strategy in GBM treatment. Its success will likely depend on multimodal approaches integrating surgical, cytotoxic and immune‐modulatory interventions that also target glioma stem‐like populations. Rational combinations that address both immune suppression and tumour heterogeneity could transform CD47 inhibition from a transient lead into a viable therapeutic path for this intractable malignancy.
- 6 November 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (21) , e70889
Open AccessTherapeutic Strategies Targeting Anti‐ CD47 Therapies in Glioblastoma Multiforme: Lead or Dead End?
Glioblastoma multiforme (GBM) remains the most aggressive primary brain tumour in adults, characterised by marked cellular heterogeneity, stem‐like subpopulations, and profound resistance to standard therapies. The failure of conventional approaches underscores the need for novel immunotherapeutic strategies that can effectively overcome tumour immune evasion. Multiple therapeutic strategies have been explored to disrupt CD47 signalling in GBM, including monoclonal antibodies, soluble SIRPα fusion proteins, recombinant or peptide fragments derived from TSP‐1, dual CD47/CD36 inhibitors, and antisense oligonucleotides. Overall, anti‐CD47 therapy represents a promising but incomplete strategy in GBM treatment. Its success will likely depend on multimodal approaches integrating surgical, cytotoxic and immune‐modulatory interventions that also target glioma stem‐like populations. Rational combinations that address both immune suppression and tumour heterogeneity could transform CD47 inhibition from a transient lead into a viable therapeutic path for this intractable malignancy.
- Open Access
Phytochemicals as Epigenetic Modulators in Chronic Diseases: Molecular Mechanisms
Phytochemicals are plant-derived bioactive compounds with antioxidant, anti-inflammatory, and epigenetic modulatory effects that may contribute to the prevention and management of chronic diseases. This review synthesizes recent evidence on the molecular mechanisms through which phytochemicals influence oxidative stress, inflammatory signaling, and epigenetic regulation. A targeted literature search of the PubMed and Web of Science databases (2015–2025) identified over 400 experimental and review studies investigating phytochemicals with documented antioxidant and epigenetic activities. Eligible articles were selected based on relevance to oxidative stress, inflammation, and DNA or histone modification pathways in chronic diseases. Data were qualitatively analyzed to highlight mechanistic links between redox balance, transcriptional regulation, and disease modulation. The results indicate that several phytochemicals, including hesperidin, phloretin, lycopene, and silybin, modulate signaling cascades—NF-κB, Nrf2, and PI3K/Akt—while also influencing DNA methylation and histone acetylation to restore gene expression homeostasis. Despite strong in vitro and in vivo evidence, translation to clinical practice remains limited by low bioavailability, lack of standardized formulations, and insufficient human trials. Future research should prioritize integrative study designs linking molecular mechanisms to clinical endpoints. Understanding the epigenetic actions of phytochemicals may guide the development of nutraceutical strategies for chronic disease prevention.
Open AccessPhytochemicals as Epigenetic Modulators in Chronic Diseases: Molecular Mechanisms
Phytochemicals are plant-derived bioactive compounds with antioxidant, anti-inflammatory, and epigenetic modulatory effects that may contribute to the prevention and management of chronic diseases. This review synthesizes recent evidence on the molecular mechanisms through which phytochemicals influence oxidative stress, inflammatory signaling, and epigenetic regulation. A targeted literature search of the PubMed and Web of Science databases (2015–2025) identified over 400 experimental and review studies investigating phytochemicals with documented antioxidant and epigenetic activities. Eligible articles were selected based on relevance to oxidative stress, inflammation, and DNA or histone modification pathways in chronic diseases. Data were qualitatively analyzed to highlight mechanistic links between redox balance, transcriptional regulation, and disease modulation. The results indicate that several phytochemicals, including hesperidin, phloretin, lycopene, and silybin, modulate signaling cascades—NF-κB, Nrf2, and PI3K/Akt—while also influencing DNA methylation and histone acetylation to restore gene expression homeostasis. Despite strong in vitro and in vivo evidence, translation to clinical practice remains limited by low bioavailability, lack of standardized formulations, and insufficient human trials. Future research should prioritize integrative study designs linking molecular mechanisms to clinical endpoints. Understanding the epigenetic actions of phytochemicals may guide the development of nutraceutical strategies for chronic disease prevention.
- Open Access
- 21 October 2025
- Published by MDPI AG in Preprints.org
Unlocking the Sugar Code: Implications and Consequences of Glycosylation in Alzheimer’s Disease and Other Tauopathies
Alzheimer’s disease (AD) is the most prevalent cause of dementia, characterized by progressive cognitive decline, amyloid-β (Aβ) plaques, and neurofibrillary tangles composed of hyperphosphorylated tau protein. Other tauopathies, including fronto-temporal lobar degeneration (FTLD), progressive supranuclear palsy (PSP), and corti-cobasal degeneration (CBD), share pathological hallmarks centered on abnormal tau biology. Increasing evidence highlights the role of post-translational modifications in modulating these pathogenic processes. Among these, glycosylation, the enzymatic attachment of glycans to proteins or lipids, has emerged as a critical regulator of pro-tein folding, trafficking, aggregation, and clearance. Both N-linked glycosylation (N-glycosylation) and O-linked glycosylation (O-glycosylation) influence tau stabil-ity, Aβ processing, receptor signaling, synaptic integrity, and neuroinflammation. Dysregulated glycosylation patterns have been documented in brains and cerebrospi-nal fluid (CSF) of AD patients, suggesting biomarker potential and novel therapeutic targets. Moreover, glycosyltransferases and glycosidases show altered expression in neurodegeneration, linking metabolic and inflammatory pathways to tauopathy pro-gression. This review synthesizes current evidence on the implications and conse-quences of glycosylation in AD and other tauopathies, integrating mechanistic, pathological, and clinical findings. We also discuss advances in glycoproteomics, the interplay between glycosylation and phosphorylation, and the translational potential of targeting glycosylation pathways for diagnosis and therapy.
- 21 October 2025
- Published by MDPI AG in Preprints.org
Open AccessUnlocking the Sugar Code: Implications and Consequences of Glycosylation in Alzheimer’s Disease and Other Tauopathies
Alzheimer’s disease (AD) is the most prevalent cause of dementia, characterized by progressive cognitive decline, amyloid-β (Aβ) plaques, and neurofibrillary tangles composed of hyperphosphorylated tau protein. Other tauopathies, including fronto-temporal lobar degeneration (FTLD), progressive supranuclear palsy (PSP), and corti-cobasal degeneration (CBD), share pathological hallmarks centered on abnormal tau biology. Increasing evidence highlights the role of post-translational modifications in modulating these pathogenic processes. Among these, glycosylation, the enzymatic attachment of glycans to proteins or lipids, has emerged as a critical regulator of pro-tein folding, trafficking, aggregation, and clearance. Both N-linked glycosylation (N-glycosylation) and O-linked glycosylation (O-glycosylation) influence tau stabil-ity, Aβ processing, receptor signaling, synaptic integrity, and neuroinflammation. Dysregulated glycosylation patterns have been documented in brains and cerebrospi-nal fluid (CSF) of AD patients, suggesting biomarker potential and novel therapeutic targets. Moreover, glycosyltransferases and glycosidases show altered expression in neurodegeneration, linking metabolic and inflammatory pathways to tauopathy pro-gression. This review synthesizes current evidence on the implications and conse-quences of glycosylation in AD and other tauopathies, integrating mechanistic, pathological, and clinical findings. We also discuss advances in glycoproteomics, the interplay between glycosylation and phosphorylation, and the translational potential of targeting glycosylation pathways for diagnosis and therapy.
- Open Access
- 2 October 2025
- Published by MDPI AG in Preprints.org
Phytochemicals as Epigenetic Modulators in Chronic Diseases; Molecular Mechanism
Phytochemicals are bioactive plant-derived compounds with significant antioxidant, anti-inflammatory, and epigenetic modulatory properties, offering promising avenues for the prevention and management of chronic diseases. Chronic conditions such as cancer, cardiovascular, neurodegenerative, metabolic, and autoimmune disorders often involve oxidative stress, inflammation, and epigenetic dysregulation. Evidence from in vitro and in vivo studies indicates that phytochemicals, including flavonoids, carotenoids, phenolic acids, organosulfur compounds, and terpenes, can attenuate oxidative damage by enhancing endogenous antioxidant defenses, modulate inflammatory signaling pathways such as NF-κB and Nrf2, and influence gene expression through the regulation of DNA methylation, histone modifications, and non-coding RNAs. Specific compounds—such as hesperidin, genistein, phloretin, lycopene, caffeic acid, p-coumaric acid, anacardic acid, allyl mercaptan, silybin, artemisinin, and geraniol—demonstrate multi-targeted actions, reversing aberrant epigenetic marks and restoring cellular homeostasis. By simultaneously acting on redox balance, inflammatory mediators, and epigenetic regulators, these natural compounds provide a mechanistic basis for chemoprevention and adjuvant therapy. However, translation into clinical applications requires rigorous trials to assess bioavailability, synergistic effects, and safety in humans. Understanding the molecular mechanisms of phytochemical action may advance novel, integrative strategies for chronic disease prevention and health promotion.
- 2 October 2025
- Published by MDPI AG in Preprints.org
Open AccessPhytochemicals as Epigenetic Modulators in Chronic Diseases; Molecular Mechanism
Phytochemicals are bioactive plant-derived compounds with significant antioxidant, anti-inflammatory, and epigenetic modulatory properties, offering promising avenues for the prevention and management of chronic diseases. Chronic conditions such as cancer, cardiovascular, neurodegenerative, metabolic, and autoimmune disorders often involve oxidative stress, inflammation, and epigenetic dysregulation. Evidence from in vitro and in vivo studies indicates that phytochemicals, including flavonoids, carotenoids, phenolic acids, organosulfur compounds, and terpenes, can attenuate oxidative damage by enhancing endogenous antioxidant defenses, modulate inflammatory signaling pathways such as NF-κB and Nrf2, and influence gene expression through the regulation of DNA methylation, histone modifications, and non-coding RNAs. Specific compounds—such as hesperidin, genistein, phloretin, lycopene, caffeic acid, p-coumaric acid, anacardic acid, allyl mercaptan, silybin, artemisinin, and geraniol—demonstrate multi-targeted actions, reversing aberrant epigenetic marks and restoring cellular homeostasis. By simultaneously acting on redox balance, inflammatory mediators, and epigenetic regulators, these natural compounds provide a mechanistic basis for chemoprevention and adjuvant therapy. However, translation into clinical applications requires rigorous trials to assess bioavailability, synergistic effects, and safety in humans. Understanding the molecular mechanisms of phytochemical action may advance novel, integrative strategies for chronic disease prevention and health promotion.
- Top Cited PapersOpen Access
- 16 August 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (16) , 7928
Immunological and Inflammatory Biomarkers in the Prognosis, Prevention, and Treatment of Ischemic Stroke: A Review of a Decade of Advancement
Ischemic stroke triggers a dynamic immune response that influences both acute damage and long-term recovery. This review synthesizes a decade of evidence on immunological and inflammatory biomarkers in ischemic stroke, emphasizing their prognostic and therapeutic significance. Following ischemic insult, levels of pro-inflammatory cytokines, such as interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), and chemokines like interleukin-8 (IL-8) rapidly rise, promoting blood–brain barrier disruption, leukocyte infiltration, and neuronal death. Conversely, anti-inflammatory mediators such as interleukin-10 (IL-10) and transforming growth factor-β (TGF-β) facilitate repair, neurogenesis, and immune regulation in later phases. The balance between these pathways determines outcomes and is reflected in circulating biomarkers. Composite hematological indices including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) offer accessible and cost-effective prognostic tools. Several biomarkers correlate with infarct size, neurological deterioration, and mortality, and may predict complications like hemorrhagic transformation or infection. Therapeutic strategies targeting cytokines, especially IL-1 and IL-6, have shown promise in modulating inflammation and improving outcomes. Future directions include personalized immune profiling, real-time cytokine monitoring, and combining immunotherapy with neurorestorative approaches. By integrating immune biomarkers into stroke care, clinicians may enhance risk stratification, optimize treatment timing, and identify candidates for novel interventions. This review underscores inflammation’s dual role and evolving therapeutic and prognostic relevance in ischemic stroke.
- 16 August 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (16) , 7928
Top Cited PapersOpen AccessImmunological and Inflammatory Biomarkers in the Prognosis, Prevention, and Treatment of Ischemic Stroke: A Review of a Decade of Advancement
Ischemic stroke triggers a dynamic immune response that influences both acute damage and long-term recovery. This review synthesizes a decade of evidence on immunological and inflammatory biomarkers in ischemic stroke, emphasizing their prognostic and therapeutic significance. Following ischemic insult, levels of pro-inflammatory cytokines, such as interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), and chemokines like interleukin-8 (IL-8) rapidly rise, promoting blood–brain barrier disruption, leukocyte infiltration, and neuronal death. Conversely, anti-inflammatory mediators such as interleukin-10 (IL-10) and transforming growth factor-β (TGF-β) facilitate repair, neurogenesis, and immune regulation in later phases. The balance between these pathways determines outcomes and is reflected in circulating biomarkers. Composite hematological indices including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) offer accessible and cost-effective prognostic tools. Several biomarkers correlate with infarct size, neurological deterioration, and mortality, and may predict complications like hemorrhagic transformation or infection. Therapeutic strategies targeting cytokines, especially IL-1 and IL-6, have shown promise in modulating inflammation and improving outcomes. Future directions include personalized immune profiling, real-time cytokine monitoring, and combining immunotherapy with neurorestorative approaches. By integrating immune biomarkers into stroke care, clinicians may enhance risk stratification, optimize treatment timing, and identify candidates for novel interventions. This review underscores inflammation’s dual role and evolving therapeutic and prognostic relevance in ischemic stroke.
- Open Access
- 21 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (14) , 7022
Harnessing Plant-Based Nanoparticles for Targeted Therapy: A Green Approach to Cancer and Bacterial Infections
This study investigates the antioxidant, antimicrobial, and antitumor activities of Taraxacum officinale (Dandelion) and Artemisia annua (Sweet Wormwood) extracts, along with their role in the green synthesis of gold (AuNPs) and silver nanoparticles (AgNPs). Bioreduction was achieved using aqueous and ethanolic extracts (100 mg/mL), enabling solvent-dependent comparisons. Nanoparticles were characterized using ultraviolet–visible spectroscopy (UV–Vis), fluorescence spectroscopy, scanning electron microscopy (SEM), dynamic light scattering (DLS), high-resolution transmission electron microscopy (HRTEM), and zeta potential analysis. Each technique revealed complementary aspects of nanoparticle morphology, size, and stability, with UV–Vis indicating aggregation states and DLS confirming solvent-related size variation even at 3–5% ethanol. Gold nanoparticles synthesized from Dandelion showed strong antibacterial activity against Staphylococcus aureus, while silver nanoparticles from both plants were effective against Escherichia coli. Cytotoxicity assays indicated that silver nanoparticles obtained from ethanolic Dandelion extract containing 3% ethanol in aqueous solution (AgNPsEETOH3%-D) significantly reduced LoVo (p = 4.58 × 10−3) and MDA-MB-231 (p = 7.20 × 10−5) cell viability, with high selectivity indices (SI), suggesting low toxicity toward normal cells. Gold nanoparticles synthesized from aqueous Dandelion extract (AuNPsEaq-D) also showed favorable SI values (2.16 for LoVo and 8.41 for MDA-MB-231). Although some formulations demonstrated lower selectivity (SI < 1.5), the findings support the therapeutic potential of these biogenic nanoparticles. Further in vivo studies and pharmacokinetic evaluations are required to validate their clinical applicability.
- 21 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (14) , 7022
Open AccessHarnessing Plant-Based Nanoparticles for Targeted Therapy: A Green Approach to Cancer and Bacterial Infections
This study investigates the antioxidant, antimicrobial, and antitumor activities of Taraxacum officinale (Dandelion) and Artemisia annua (Sweet Wormwood) extracts, along with their role in the green synthesis of gold (AuNPs) and silver nanoparticles (AgNPs). Bioreduction was achieved using aqueous and ethanolic extracts (100 mg/mL), enabling solvent-dependent comparisons. Nanoparticles were characterized using ultraviolet–visible spectroscopy (UV–Vis), fluorescence spectroscopy, scanning electron microscopy (SEM), dynamic light scattering (DLS), high-resolution transmission electron microscopy (HRTEM), and zeta potential analysis. Each technique revealed complementary aspects of nanoparticle morphology, size, and stability, with UV–Vis indicating aggregation states and DLS confirming solvent-related size variation even at 3–5% ethanol. Gold nanoparticles synthesized from Dandelion showed strong antibacterial activity against Staphylococcus aureus, while silver nanoparticles from both plants were effective against Escherichia coli. Cytotoxicity assays indicated that silver nanoparticles obtained from ethanolic Dandelion extract containing 3% ethanol in aqueous solution (AgNPsEETOH3%-D) significantly reduced LoVo (p = 4.58 × 10−3) and MDA-MB-231 (p = 7.20 × 10−5) cell viability, with high selectivity indices (SI), suggesting low toxicity toward normal cells. Gold nanoparticles synthesized from aqueous Dandelion extract (AuNPsEaq-D) also showed favorable SI values (2.16 for LoVo and 8.41 for MDA-MB-231). Although some formulations demonstrated lower selectivity (SI < 1.5), the findings support the therapeutic potential of these biogenic nanoparticles. Further in vivo studies and pharmacokinetic evaluations are required to validate their clinical applicability.
- Open Access
- 14 July 2025
- Published by MDPI AG in Preprints.org
Immunological and Inflammatory Biomarkers in the Prognosis and Prevention of Ischemic Stroke: A Review of a Decade of Advancement
Ischemic stroke triggers a dynamic immune response that influences both acute damage and long-term recovery. This review synthesizes a decade of evidence on immunolog-ical and inflammatory biomarkers in ischemic stroke, emphasizing their prognostic and therapeutic significance. Following ischemic insult, pro-inflammatory cytokines such as interleukin-1β (IL-1β), IL-6, tumour necrosis factor-α (TNF-α), and chemokines like IL-8 rapidly rise, promoting blood-brain barrier disruption, leukocyte infiltration, and neu-ronal death. Conversely, anti-inflammatory mediators such as IL-10 and TGF-β facilitate repair, neurogenesis, and immune regulation in later phases. The balance between these pathways determines outcomes and is reflected in circulating biomarkers. Composite hematological indices including neutrophil-to-lymphocyte ratio (NLR), plate-let-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) offer accessible and cost-effective prognostic tools. Several biomarkers correlate with infarct size, neurological deterioration, and mortality, and may predict complications like hemorrhagic transformation or infection. Therapeutic strategies targeting cytokines, especially IL-1 and IL-6, have shown promise in modulating inflammation and im-proving outcomes. Future directions include personalized immune profiling, real-time cytokine monitoring, and combining immunotherapy with neurorestorative approach-es. By integrating immune biomarkers into stroke care, clinicians may enhance risk stratification, optimize treatment timing, and identify candidates for novel interven-tions. This review underscores inflammation’s dual role and evolving therapeutic and prognostic relevance in ischemic stroke.
- 14 July 2025
- Published by MDPI AG in Preprints.org
Open AccessImmunological and Inflammatory Biomarkers in the Prognosis and Prevention of Ischemic Stroke: A Review of a Decade of Advancement
Ischemic stroke triggers a dynamic immune response that influences both acute damage and long-term recovery. This review synthesizes a decade of evidence on immunolog-ical and inflammatory biomarkers in ischemic stroke, emphasizing their prognostic and therapeutic significance. Following ischemic insult, pro-inflammatory cytokines such as interleukin-1β (IL-1β), IL-6, tumour necrosis factor-α (TNF-α), and chemokines like IL-8 rapidly rise, promoting blood-brain barrier disruption, leukocyte infiltration, and neu-ronal death. Conversely, anti-inflammatory mediators such as IL-10 and TGF-β facilitate repair, neurogenesis, and immune regulation in later phases. The balance between these pathways determines outcomes and is reflected in circulating biomarkers. Composite hematological indices including neutrophil-to-lymphocyte ratio (NLR), plate-let-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) offer accessible and cost-effective prognostic tools. Several biomarkers correlate with infarct size, neurological deterioration, and mortality, and may predict complications like hemorrhagic transformation or infection. Therapeutic strategies targeting cytokines, especially IL-1 and IL-6, have shown promise in modulating inflammation and im-proving outcomes. Future directions include personalized immune profiling, real-time cytokine monitoring, and combining immunotherapy with neurorestorative approach-es. By integrating immune biomarkers into stroke care, clinicians may enhance risk stratification, optimize treatment timing, and identify candidates for novel interven-tions. This review underscores inflammation’s dual role and evolving therapeutic and prognostic relevance in ischemic stroke.